---
title: "Soligenix (SNGX) Receives a Buy from Alliance Global Partners"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295262411.md"
description: "Alliance Global Partners analyst James Molloy maintained a Buy rating on Soligenix (SNGX) with a $1.50 price target. This aligns with the current moderate buy consensus and average price target for the stock."
datetime: "2026-08-07T17:15:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295262411.md)
  - [en](https://longbridge.com/en/news/295262411.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295262411.md)
generator: "portal-rs"
---

# Soligenix (SNGX) Receives a Buy from Alliance Global Partners

In a report released today, James Molloy from Alliance Global Partners maintained a Buy rating on Soligenix, with a price target of $1.50.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Molloy covers the Healthcare sector, focusing on stocks such as Tonix Pharma, SELLAS Life Sciences Group, and Verastem. According to TipRanks, Molloy has an average return of -17.5% and a 26.64% success rate on recommended stocks. 

Currently, the analyst consensus on Soligenix is a Moderate Buy with an average price target of $1.50.

### Related Stocks

- [SNGX.US](https://longbridge.com/en/quote/SNGX.US.md)
- [TNXP.US](https://longbridge.com/en/quote/TNXP.US.md)
- [SLS.US](https://longbridge.com/en/quote/SLS.US.md)
- [VSTM.US](https://longbridge.com/en/quote/VSTM.US.md)

## Related News & Research

- [Soligenix Q2 net loss narrows as R&D expenses fall](https://longbridge.com/en/news/295228776.md)
- [AcuCort notifies availability of August 2026 newsletter press release](https://longbridge.com/en/news/297505730.md)
- [Shaw and Partners Sticks to Their Buy Rating for Beforepay Group Limited (B4P)](https://longbridge.com/en/news/297573018.md)
- [Analyst Maintains Buy Rating on Teladoc with Unchanged $10.50 Price Target Amid Strategic Transition and New CFO Appointment](https://longbridge.com/en/news/297585950.md)
- [Barclays Reaffirms Their Buy Rating on Airbus Group SE (EADSF)](https://longbridge.com/en/news/297615153.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**